Federal Circuit Rules For Shwarz Pharma In Suit Over Univasc Patent

Law360, New York (February 1, 2004, 12:00 AM EST) -- The U.S. Court of Appeals for the Federal Circuit has vacated a lower court’s decision that supported Israeli generics maker Teva's right to sell a generic form of Schwarz Pharma’s hypertension drug Univasc.

The U.S. District Court for the District of New Jersey had found that Teva's product, Moexipril HCl Tablets,would not infringe U.S. Patent No. 4,743,450, asserted by Schwarz Pharma as licensee of Warner Lambert. However, the Court of Appeals has remanded the case to the District Court for further proceedings, Teva said.

“Yesterday's ruling...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.